CRISPR-Cas9 SCN9A Editing for Precise Pain-Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genome engineering technologies for treating SCN9A-related disorders lack precision and reproducibility, and there is a need for safe and effective treatments that can provide permanent changes to the genome with minimal intervention.
Innovation Solution
Utilizing CRISPR/Cas9 and Cpf1 endonucleases to introduce targeted single-strand or double-strand breaks in the SCN9A gene or its regulatory elements, enabling permanent insertions, deletions, or mutations to reduce or eliminate SCN9A gene expression, with methods including ex vivo and in vivo approaches using iPSCs and mesenchymal stem cells differentiated into neurons for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If early random insertion technologies are used to insert transgenes, then the insertion process is simple, but the precision and reproducibility are poor leading to severe unwanted effects
Solution Approach 1:
The patent employs guide RNA molecules as intermediaries that direct the Cas9 endonuclease to specific genomic locations. This mediator system enables precise targeting of the SCN9A gene without random insertion, resolving the contradiction between ease of manufacture and manufacturing precision by introducing a programmable guidance mechanism
Solution Approach 2:
The patent replaces the mechanical/random insertion process with a programmable molecular recognition system. The guide RNA sequence specifically binds to complementary DNA sequences through base pairing, substituting the non-specific mechanical insertion with a sequence-specific molecular recognition mechanism that achieves both precision and reproducibility
2Manufacturing precision
If zinc finger nucleases or TALENs are used to modify specific DNA areas, then the precision of alteration is increased, but the device complexity and treatment cost increase
Solution Approach 1:
The patent employs a universal CRISPR-Cas9 system where a single Cas9 endonuclease can target any genomic location by simply changing the guide RNA sequence. This multi-functional platform replaces the need for different complex protein systems (ZFNs, TALENs) for different targets, reducing device complexity while maintaining high precision alteration capability
Solution Approach 2:
The patent achieves different targeting specificities by changing the nucleotide sequence parameter of the guide RNA rather than changing the protein structure. This simple parameter change (RNA sequence) enables targeting of different genomic locations including the SCN9A gene, avoiding the complexity of designing different protein complexes for each target
3Reliability
If multiple treatments are administered to address genetic disorders, then the treatment coverage is comprehensive, but the treatment duration and patient burden increase
Solution Approach 1:
The patent performs preliminary action by introducing permanent genetic modifications to patient-specific induced pluripotent stem cells ex vivo before administration. This preliminary genetic editing ensures long-lasting therapeutic effects from a single treatment, reducing the need for repeated administrations and decreasing patient burden while maintaining treatment reliability
Solution Approach 2:
The patent enables the edited stem cells to self-renew and differentiate into functional neurons that permanently express the corrected or knocked-out SCN9A gene. This self-service mechanism allows the treatment to maintain its effectiveness over time without requiring external intervention or repeated dosing, resolving the contradiction between treatment reliability and duration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves permanent genomic alterations to treat SCN9A-related conditions by reducing or eliminating SCN9A gene products, potentially providing a single-treatment remedy for pain-related disorders with high specificity and efficiency.
Implementation Method 1
introducing into the cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the SCN9A gene
Data Source
AI summary
The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN9A gene in a cell by genome editing.